-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
J.W. Cole Advisors Inc. Has $88,000 Stock Holdings in VBI Vaccines Inc. (NASDAQ:VBIV)
J.W. Cole Advisors Inc. Has $88,000 Stock Holdings in VBI Vaccines Inc. (NASDAQ:VBIV)
J.W. Cole Advisors Inc. trimmed its position in VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) by 27.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,100 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. J.W. Cole Advisors Inc.'s holdings in VBI Vaccines were worth $88,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the company. E Fund Management Co. Ltd. raised its holdings in VBI Vaccines by 98.1% during the 1st quarter. E Fund Management Co. Ltd. now owns 53,148 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 26,320 shares during the period. GSA Capital Partners LLP acquired a new stake in VBI Vaccines during the 4th quarter worth approximately $257,000. Nisa Investment Advisors LLC raised its holdings in VBI Vaccines by 1,099.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 126,800 shares of the biopharmaceutical company's stock worth $210,000 after buying an additional 116,230 shares during the period. Grimes & Company Inc. raised its holdings in VBI Vaccines by 19.6% during the 1st quarter. Grimes & Company Inc. now owns 281,077 shares of the biopharmaceutical company's stock worth $467,000 after buying an additional 46,116 shares during the period. Finally, Wealthsource Partners LLC acquired a new stake in VBI Vaccines during the 1st quarter worth approximately $238,000. 39.96% of the stock is currently owned by institutional investors and hedge funds.
Get VBI Vaccines alerts:VBI Vaccines Price Performance
NASDAQ VBIV opened at $0.73 on Friday. The company has a quick ratio of 2.19, a current ratio of 2.29 and a debt-to-equity ratio of 0.20. VBI Vaccines Inc. has a 12-month low of $0.64 and a 12-month high of $3.49. The company has a market capitalization of $189.22 million, a PE ratio of -1.88 and a beta of 1.86. The firm's 50 day moving average is $0.93 and its 200-day moving average is $1.09.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). VBI Vaccines had a negative net margin of 15,391.36% and a negative return on equity of 75.37%. The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.70 million. Equities research analysts anticipate that VBI Vaccines Inc. will post -0.37 earnings per share for the current fiscal year.Analyst Ratings Changes
Separately, Raymond James dropped their target price on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
See Also
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
J.W. Cole Advisors Inc. trimmed its position in VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) by 27.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,100 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. J.W. Cole Advisors Inc.'s holdings in VBI Vaccines were worth $88,000 at the end of the most recent quarter.
根据J.W.Cole Advisors Inc.最近提交给美国证券交易委员会(美国证券交易委员会)的13F文件，该公司在第一季度将其在VBI疫苗公司(VBI Vaccines Inc.)的头寸削减了27.4%。在此期间，该公司出售了20,000股票，拥有这家生物制药公司53,100股票。截至最近一个季度末，J.W.Cole Advisors Inc.持有的VBI疫苗价值8.8万美元。
A number of other hedge funds have also modified their holdings of the company. E Fund Management Co. Ltd. raised its holdings in VBI Vaccines by 98.1% during the 1st quarter. E Fund Management Co. Ltd. now owns 53,148 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 26,320 shares during the period. GSA Capital Partners LLP acquired a new stake in VBI Vaccines during the 4th quarter worth approximately $257,000. Nisa Investment Advisors LLC raised its holdings in VBI Vaccines by 1,099.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 126,800 shares of the biopharmaceutical company's stock worth $210,000 after buying an additional 116,230 shares during the period. Grimes & Company Inc. raised its holdings in VBI Vaccines by 19.6% during the 1st quarter. Grimes & Company Inc. now owns 281,077 shares of the biopharmaceutical company's stock worth $467,000 after buying an additional 46,116 shares during the period. Finally, Wealthsource Partners LLC acquired a new stake in VBI Vaccines during the 1st quarter worth approximately $238,000. 39.96% of the stock is currently owned by institutional investors and hedge funds.
其他一些对冲基金也调整了对该公司的持股。易方达基金管理有限公司在第一季度增持VBI疫苗98.1%。易方达基金管理有限公司现在持有53,148股这家生物制药公司的股票，价值88,000美元，在此期间又购买了26,320股。GSA Capital Partners LLP在第四季度收购了VBI疫苗公司的新股份，价值约25.7万美元。NISA Investment Advisors LLC在第一季度将其在VBI疫苗的持有量增加了1099.6%。NISA Investment Advisors LLC现在持有这家生物制药公司的12.68万股票，价值21万美元，在此期间又购买了116,230股票。Grimes&Company Inc.在第一季度将其在VBI疫苗公司的持股增加了19.6%。Grimes&Company Inc.现在持有281,077股这家生物制药公司的股票，价值467,000美元，在此期间又购买了46,116股。最后，Wealthsource Partners LLC在第一季度收购了VBI疫苗公司价值约23.8万美元的新股份。该公司39.96%的股票目前由机构投资者和对冲基金持有。
VBI Vaccines Price Performance
VBI疫苗的价格表现
NASDAQ VBIV opened at $0.73 on Friday. The company has a quick ratio of 2.19, a current ratio of 2.29 and a debt-to-equity ratio of 0.20. VBI Vaccines Inc. has a 12-month low of $0.64 and a 12-month high of $3.49. The company has a market capitalization of $189.22 million, a PE ratio of -1.88 and a beta of 1.86. The firm's 50 day moving average is $0.93 and its 200-day moving average is $1.09.
纳斯达克VBIV上周五开盘报0.73美元。该公司的速动比率为2.19，流动比率为2.29，债务权益比为0.20。VBI疫苗公司的股价为0.64美元的12个月低点和3.49美元的12个月高位。该公司市值为1.8922亿美元，市盈率为-1.88，贝塔系数为1.86。该公司的50日移动均线切入位在0.93美元，200日移动均线切入位在1.09美元。
Analyst Ratings Changes
分析师评级发生变化
Separately, Raymond James dropped their target price on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
另外，雷蒙德·詹姆斯在8月9日周二的一份报告中将VBI疫苗的目标价从6.00美元下调至5.00美元，并将该股的评级定为“强力买入”。
About VBI Vaccines
关于VBI疫苗
(Get Rating)
(获取评级)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
VBI疫苗公司是一家生物制药公司，开发和销售用于治疗传染病和免疫肿瘤学的疫苗。该公司提供一种预防性乙肝疫苗Sci-B-Vac。它还参与VBI-2601(BRII-179)的开发，VBI-2601(BRII-179)是治疗慢性乙肝感染的免疫治疗候选药物。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免费获取StockNews.com关于VBI疫苗的研究报告(VBIV)
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗？
- 这些机构持有达顿餐饮国际公司的股份
- 这三大股利支付者也拥有强劲的价格增长
- 住房建设的黄金时代已经结束了吗？
- 天然气价格继续回升，这些股票应该会受益
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到VBI疫苗的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对VBI疫苗和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧